News ArticleCipla Ltd Issues Notice of Final Hearing for Amalgamation Scheme with Inzpera Healthsciences
Notice published in Business Standard and Navshakti as per National Company Law Tribunal Mumbai Bench directive
Cipla Ltd published a notice of final hearing regarding the Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited (Transferor Company) into Cipla Ltd (Transferee Company), as directed by the National Company Law Tribunal, Mumbai Bench, complying with SEBI regulations.
Cipla Ltd
Acquisition / Amalgamation / Merger / Demerger
Cipla Ltd has published a newspaper notice for the final hearing of its Scheme of Amalgamation by absorption of Inzpera Healthsciences Limited, complying with the National Company Law Tribunal Mumbai Bench directives and SEBI listing regulations.
The notice was published in prominent newspapers Business Standard (English) and Navshakti (Marathi) on 5th November 2026.
This scheme involves absorption of Inzpera Healthsciences Limited (the Transferor Company) by Cipla Ltd (the Transferee Company), affecting their shareholders accordingly.
The announcement is made under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30, which governs disclosure of material events by listed companies.
The publishing of the notice marks a significant procedural milestone in the court-driven merger process under the National Company Law Tribunal's supervision.
Highlights
- Scheme of Amalgamation final hearing notice issued for Cipla Ltd and Inzpera Healthsciences Limited.
- Published in Business Standard and Navshakti newspapers on 5th November, 2026.
- Compliance with SEBI LODR Regulations, 2015 Regulation 30.
- Approval process overseen by the National Company Law Tribunal, Mumbai Bench.
- This notice impacts shareholders of both companies involved in the amalgamation.
Key Data Snapshot
What happened
- Cipla Ltd published a newspaper notice of the final hearing regarding the Scheme of Amalgamation with Inzpera Healthsciences Limited.
- The notice is issued in compliance with directions from the National Company Law Tribunal (Mumbai Bench).
- The publication appeared in Business Standard (English) and Navshakti (Marathi).
Regulatory and governance context
- The announcement is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Scheme of Amalgamation is a court-approved process under the jurisdiction of the National Company Law Tribunal.
- The notice informs shareholders of the final hearing that will decide on the amalgamation.
Next milestones
- The final hearing by the National Company Law Tribunal is the decisive procedural step before completion of the amalgamation.
- Shareholders of Cipla Ltd and Inzpera Healthsciences Limited are directly impacted by the scheme's approval outcome.
- Further disclosures and compliance filings will follow based on the tribunal's decisions.
Highlights
- Scheme of Amalgamation final hearing notice issued for Cipla Ltd and Inzpera Healthsciences Limited.
- Published in Business Standard and Navshakti newspapers on 5th November, 2026.
- Compliance with SEBI LODR Regulations, 2015 Regulation 30.
- Approval process overseen by the National Company Law Tribunal, Mumbai Bench.
- This notice impacts shareholders of both companies involved in the amalgamation.
Disclosures
- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30
More News on Acquisition / Amalgamation / Merger / Demerger
View allLatest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.
Sundaram Finance Limited to Acquire Entire Stake in Sundaram Alternate Assets Limited at Cost up to ₹75 Crore
Sundaram Finance Limited has approved the acquisition of 100% equity shares in Sundaram Alternate Assets Limited from its existing wholly-owned subsidiary, Sundaram Asset Management Company Limited, for up to ₹75 crore in cash. The move will make Sundaram Alternate Assets Limited a direct wholly-owned subsidiary of Sundaram Finance Limited, streamlining the group’s shareholding structure.
Read Full Story
Bharat Forge Posts Rs. 6,922.24 Million Standalone Profit for H1 FY2027 and Approves Rs. 2,905.08 Million Investment in Kalyani Strategic
Bharat Forge Limited reported a standalone profit of Rs. 6,922.24 million for the half year ended September 30, 2026, and declared unaudited financial results for the quarter and half year. The company also approved an investment of up to Rs. 2,905.08 million in its wholly owned subsidiary, Kalyani Strategic Systems Limited.
Read Full Story
Physicswallah Limited Raises Stake in Utkarsh Classes to 87.75% via INR 2.56 Lakh Equity Acquisition
Physicswallah Limited has approved the acquisition of 25,599 equity shares in its subsidiary Utkarsh Classes & Edutech Private Limited for INR 2,55,990, increasing its shareholding from 75.50% to 87.75%. This transaction amends the prior valuation mechanism and eliminates a final acquisition tranche, with completion expected within three months.
Read Full Story
